Illumina (ILMN) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson (JNJ), and Novartis (NVS).

Under the collaboration, deCODE Genetics will process the samples from the UK Biobank using Illumina's Protein Prep solution, the company said.

The data generated from the study will be made available to the scientific research community, with the first tranche of the data expected to be released in H2.

Illumina Protein Prep has been in early access limited release and is expected to fully launch in H1.